NCT01642433

Prazosin for Smoking Cessation

Prazosin as a Novel Treatment for Smoking Cessation

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 1 (actual)
• Sponsor: Centre for Addiction and Mental Health · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Accepted

Summary

The most likely outcome of smoking cessation attempts is relapse, underscoring the need to advance novel treatments. Preclinical research shows that the noradrenergic system is critical for modulating drug-seeking behavior and recent findings indicate that the α1-adrenergic antagonist prazosin reduces nicotine self-administration and reinstatement. Presently, data on prazosin's effects on nicotine-related behaviour in humans is lacking. An efficient method for screening novel smoking cessation medications is to integrate human laboratory paradigms in the context of brief, randomized trials of smoking cessation that include smokers motivated to quit. This study aims to provide an initial test of prazosin for smoking cessation by implementing a brief, randomized trial that will include both human laboratory and clinical phenotypes. This approach will allow an efficient but sensitive method for medication screening that maximizes clinical validity.

Conditions

• Nicotine Dependence

Interventions

Type	Name	Description
DRUG	Placebo	Placebo capsules, 3x daily
DRUG	Prazosin	Prazosin medication, 3x daily dosing, up to 15mg/day

Timeline

• Start date: 2012-07-01
• Primary completion: 2013-09-01
• Completion: 2013-09-01
• First posted: 2012-07-17
• Last updated: 2015-07-16

Locations

1 site across 1 country: Canada